Építés alatt – nem éles oldal
Belépés
Résztvevőt keresKorai 1. fázis

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

A legfontosabb adatok

Ki végzi
DSciLab Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
18 fő, tervezett
Kezdés
2025. dec. 31.
Várható befejezés
2029. ápr.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Group 1: DSL101 Low dose
  • Group 2: DSL101 Medium dose
  • Group 3: DSL101 High dose
A regiszteradat frissítve
2026. január 20.

Ki vehet részt

The trial is looking for adults with Wilson's disease that is well controlled on standard treatment. They will get DSL101 as infusions into a vein.

Életkor
18 years or older
Nem
All sexes can join
A betegség stádiuma
Wilson's disease diagnosed at least one year before screening, with a Leipzig score ≥4. The disease must be stable and well controlled: serum NCC ≥ 25 μg/L and ≤ 150 μg/L, urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours, ALT < 2 times the upper limit of normal.
Korábbi kezelés
At least 6 months of standard treatment (such as D-penicillamine, trientine or zinc) with no drug or dose change for at least 6 months. At least six months of low copper diet before screening. People can keep their usual treatment.
Biomarker vagy leletérték
Mutations in both copies of the ATP7B gene, confirmed by laboratory tests. Ceruloplasmin level <0.1g/L.
A részvétel fő kizáró okai
  • Severe complications of Wilson's disease, such as nerve or mental disorders
  • Past liver transplant, other liver disease, or MELD score >13
  • Other diseases causing anemia, or nervous system diseases such as Parkinson's disease or epilepsy
  • Active hepatitis B or C, or HIV antibody positive
  • Pregnant or breastfeeding women
A regiszter összes feltétele (23)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Age ≥18 years old, gender not limited
  • Meet the diagnostic criteria f Wilson's Disease in "Guidelines for Diagnosis and Treatment of Wilson's Disease (2022 Edition)", with a Leipzig score ≥4, at least one year between diagnosis and screening; ceruloplasmin level <0.1g/L
  • Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene
  • Low copper diet for at least six months befoer screening and willing to continue low copper diet during study
  • Fertile subjects agreed to adopt reliable contrraceptive methods from the screening until 6 months after the last administration
  • The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment
  • The subject's condition was fully controlled after treatment, and its definition must meet all of the following conditions:; Serum NCC level ≥ 25 μg/L and ≤ 150 μg/L; Urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours; ALT < 2 times of upper limit of normal value (ULN); The investigator believes that no other laboratory values or clinical symptoms would stop current standard therapy
  • Subjects with good compliance, who can understand and cooperate to complete the requirements of protocol
  • The subjects voluntarily participated in the trial and signed the informed consent form

Ki nem vehet részt

  • Allergy or intolerance to the investigational drug
  • History of gastrointestinal bleeding within six months before screening
  • Subjects with history of moderate to severe depression, suicidal thoughts or behaviors and serious psychiatric within 6 months prior to screening
  • Subjects who have participated other clinical trial within 3 months prior to screening or plan to participate during the clinical trial
  • Wilson's disease is accompanied by severe complications such as neurological and mental disorders
  • History of liver transplantation
  • Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver malignancy, etc.; Subjects with Model for end-stage liver disease score (MELD)>13
  • Other diseases that can cause hemolysis or anemia, such as erythrocytosis, Mediterranean anemia, hemolytic anemia, various causes of infection, large area burns, etc
  • Other diseases that can cause dysfunction of the nervous system, such as Parkinson's disease, Parkinson syndrome, various causes of dystonia, chorea, primary tremor, epilepsy, mental abnormalities (such as history of schizophrenia or suicide attempts), etc
  • Subjects who have uncontrolled diseases of thr heart, liver, kidneys, endocrine system, digestive tract, metabolism, blood, or malignant tumors
  • Active hepatitis B virus infection or active hepatitis C virus infection, or human immunodeficiency virus antibody positive
  • Screening period laboratory examination indicators:; Hemoglobin < 90 g/L; Creatinine clearance ≤30 mL/min, or glomerular filtration rate <45 mL/min/1.73 m²; TBil≥2×ULN,ALP/TBil<4,AST/ALT>2.2; Platelets < 70 ×10\^9/L; Neutrophils < 1.0 × 10\^9 /L
  • Pregnant women or lactating women
  • Investigators evaluate other subjects who are not suitable to participate in this clinical trial

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor
  • Wilsons disease

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.

A vizsgálat 3 csoportja

  • Group 1: DSL101A vizsgált kezelés

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Kezelés: Group 1: DSL101 Low dose

  • Group 2: DSL101A vizsgált kezelés

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Kezelés: Group 2: DSL101 Medium dose

  • Group 3: DSL101A vizsgált kezelés

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Kezelés: Group 3: DSL101 High dose

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07240896: ki vehet részt
A regiszteradat frissítve
2026. január 20.